Gabapentin Capsule
Product Images NDC 43353-075

Product Visual Gallery

This gallery contains 15 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 43353-075). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Aphena Pharma Solutions - Tennessee, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Bottle Label 300mg (43353 0075 30)

Gabapentin 300 mg capsules packaging label showing a container of 30 oral capsules. The label includes storage instructions, manufacturer Watson Pharma Private Limited in India, and repackager Aphena Pharma Solutions - Tennessee, LLC in Cookeville, TN. The label also features NDC number 43353-0075-30 and barcodes.*

FDA Label Image

Bottle Label 400mg (43353 0081 60)

Packaging label for Gabapentin 400 mg oral capsules, containing 90 capsules. The label shows the product name, strength, quantity, barcodes, storage instructions, and manufacturer information. It is manufactured by Watson Pharma Private Limited, Verna, India, and repackaged by Aphena Pharma Solutions - Tennessee, LLC in Cookeville, TN. The label indicates prescription use (Rx Only).*

FDA Label Image

Aphena Pharma Solutions (TN)

FDA Label Image

2 (Gabapentin 1)

An illustration showing the formula for calculating creatinine clearance (CLCr) based on age (years), weight (kg), serum creatinine (mg/dL), and a factor for female patients. The formula is not specific to any drug product.*

FDA Label Image

1 (Gabapentin 10)

Gabapentin 400 mg oral capsules contained in a plastic blister pack. The blister shows four capsules, each with one side visible in brown color and the other side white. The image is a top-down view of the capsules inside the clear plastic packaging.*

FDA Label Image

1 (Gabapentin 11)

Gabapentin 300 mg oral capsules bottle label. The label is primarily white with blue and orange accents. It displays the proprietary name Gabapentin, the strength of 300 mg per capsule, and the dosage form as capsules. The labeler is Aphena Pharma Solutions - Tennessee, LLC. The label includes a barcode area and other standard pharmaceutical labeling information.*

FDA Label Image

1 (Gabapentin 12)

Gabapentin 300 mg oral capsules in a clear plastic bottle with a white child-resistant cap. The white label features black and green text, including the product name, strength (300 mg), dosage form (capsule), and the labeler, Aphena Pharma Solutions - Tennessee, LLC. The bottle size or count is not visible.*

FDA Label Image

1 (Gabapentin 2)

Gabapentin 400 mg oral capsules in a plastic bottle with a white child-resistant cap. The label includes the product name Gabapentin, strength 400 mg, dosage form capsules, and the labeler Aphena Pharma Solutions - Tennessee, LLC. The bottle appears sealed, displaying regulatory and identification markings.*

FDA Label Image

1 (Gabapentin 3)

Gabapentin 300 mg oral capsules packaged in a blister card. The packaging shows a clear blister strip with multiple individual capsules arranged in two rows. The label includes the product name Gabapentin, strength 300 mg, and the labeler Aphena Pharma Solutions - Tennessee, LLC.*

FDA Label Image

1 (Gabapentin 4)

Gabapentin 300 mg oral capsules by Aphena Pharma Solutions - Tennessee, LLC. The label displays the product name, strength of 300 mg, and dosage form as capsules. The bottle shown is brown with a white and blue label and a white screw cap.*

FDA Label Image

1 (Gabapentin 5)

Chemical structure diagram of gabapentin showing a cyclohexane ring bound to amino and carboxymethyl groups.*

FDA Label Image

1 (Gabapentin 6)

This line graph compares mean pain scores over 8 weeks between a placebo group and a gabapentin 3600 mg/day group. The x-axis represents weeks including a baseline, while the y-axis shows mean pain scores. The graph shows a decrease in pain scores for the gabapentin group during both a 4-week dose titration period and a 4-week fixed dose period, with the placebo group showing relatively stable pain scores.*

FDA Label Image

2 (Gabapentin 7)

A line graph depicting mean pain scores over a 7-week period across three groups: placebo, Gabapentin 1800 mg/day, and Gabapentin 2400 mg/day. The x-axis represents weeks, including a 3-week dose titration period and a 4-week fixed dose period. The y-axis shows the mean pain score values from 0 to 10. Gabapentin groups show a decreasing trend in pain scores compared to placebo.*

FDA Label Image

3 (Gabapentin 8)

A bar graph comparing percentages between placebo (PBO) and gabapentin (GBP) treatments in two studies. Study 1 shows 12% for PBO and 29% for GBP 3600 mg. Study 2 shows 14% for PBO, 32% for GBP 1800 mg, and 34% for GBP 2400 mg. Statistical significance is indicated with p-values less than 0.01 and 0.001.*

FDA Label Image

4 (Gabapentin 9)

A scatter plot showing the percentage difference versus daily dose in milligrams for three studies labeled a, b, and c. The doses range from 600 mg to 1800 mg on the x-axis, with the percentage difference on the y-axis from 2% to 22%. Study a is represented with black squares, study b with gray squares, and study c with white squares, each showing data points at various doses.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.